Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Investigational Combination Telmisartan And Amlodipine Shows Effective And Well-tolerated 24-hour Blood Pressure Control In Hypertensive Patients
Data presented today at the 19th Scientific Meeting of the European Society of Hypertension, Milan, Italy has demonstrated that treatment with an investigational combination of telmisartan (an angiotensin receptor blocker [ARB]) and amlodipine (a calcium-channel blocker [CCB]) shows substantial and sustained 24-hour blood pressure (BP) lowering and is well-tolerated in a range of patients with hypertension at risk of cardiovascular (CV) events. This includes patients with Type 2 diabetes, obese patients, the elderly, black patients and those not controlled by amlodipine alone.1-8

Conference: Discovery Partnerships: Academia & Industrial Interactions
Opal Events is proud to present our next exciting conference Drug Discovery Partnerships: Academia & Industrial Interactions , to be held at the Hyatt Regency in Boston on October 28-30, 2009.
News of the day
The Personalities Making News Around Health Reform
Sen. Chris Dodd has taken the reins on health care reform while he juggles other bills and a tough re-election campaign, Roll Call reports.
Mental Health

What Is The Risk Of Obesity While Taking Antidepressant Drugs?

Cross-sectional studies have reported an association between major depressive episode (MDE) and obesity. The objective of this longitudinal analysis was to determine whether MDE increase the risk of becoming obese over a 10-year period. Data from the Canadian National Population Health Survey (NPHS) were used, a longitudinal study of a representative cohort of household residents in Canada. The incidence of obesity, defined as a body mass index (BMI) of 30, was evaluated in respondents who were 18 years or older at the time of a baseline interview in 1994. MDE was assessed using a brief diagnostic instrument. At the end of the investigation, the risk of obesity was not elevated in association with MDE, either in unadjusted or covariate-adjusted analyses. The strongest predictor of obesity was a BMI in the overweight (but not obese) range. Effects were also seen for (younger) age, (female) sex, a sedentary activity pattern, low income and exposure to antidepressant medications. Unexpectedly, significant effects were seen for serotonin-reuptake-inhibiting antidepressants and venlafaxine, but neither for tricyclic antidepressants nor antipsychotic medications. MDE does not appear to increase the risk of obesity. The cross-sectional associations that have been reported, albeit inconsistently, in the literature probably represent an effect of obesity on MDE risk. Pharmacologic treatment with antidepressants may be associated with an increased risk of obesity, and strategies to offset this risk may be useful in clinical practice. Psychotherapy and Psychosomatics


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009